VEGFR
VEGFR产品
目录号 | 产品描述 | 文献引用 | 实验数据 |
---|---|---|---|
S1040 |
Sorafenib TosylateSorafenib Tosylate (Bay 43-9006) 是Raf-1和B-Raf的多重激酶抑制剂,无细胞试验中IC50分别为6 nM和22 nM。Sorafenib 还可抑制VEGFR-2、VEGFR-3、PDGFR-β、Flt-3和c-KIT,对应的IC50值分别为90 nM、20 nM、57 nM、59 nM和68 nM。Sorafenib Tosylate 可诱导autophagy、apoptosis并激活ferroptosis,并具有抗肿瘤活性。 |
![]() ![]()
Inhibition of breast cancer cell growth using sorafenib. MCF-7 breast cancer cells were treated with increasing concentrations of sorafenib for 5 days. Cell number was measured using a colorimetric growth assay (crystal violet stain) and expressed relative to DMSO treated control cells. |
|
S1042 |
Sunitinib MalateSunitinib Malate是一种多靶点RTK抑制剂,作用于VEGFR2 (Flk-1)和 PDGFRβ,在无细胞试验中IC50分别为80 nM 和2 nM,也会抑制c-Kit的活性。Sunitinib Malate 可有效地抑制 Ire1α 的自身磷酸化。Sunitinib Malate 可增加 death receptor 和 线粒体依赖的凋亡 mitochondrial-dependent apoptosis。 |
![]() ![]() Sunitinib decreases FLT-3 and RET phosphor ylation but increases ERK phosphorylation in a time-dependent manner. H295R and SW13 cells were treated with sunitinib (10 nM) for various time points as indi-cated. Cell lysates were prepared and phospho-FLT-3, RET, and ERK levels were monitored by Western Blot-ting. Re-probing against FLT-3, RET, and ERK was done to ensure equal protein loading. |
|
S1029 |
Lenalidomide (CC-5013)Lenalidomide (CC-5013)是一种TNF-α分泌抑制剂,在PBMCs中IC50为13 nM。Lenalidomide (CC-5013) 是 ubiquitin E3 ligase cereblon (CRBN) 的配体,它通过CRBN-CRL4泛素连接酶引起两个淋巴样转录因子IKZF1和IKZF3的选择性泛素化和降解。Lenalidomide 可促进 cleaved caspase-3 的表达、抑制 VEGF 的表达并诱导凋亡。 |
![]() ![]()
Effect of lenalidomide treatment (50 mg/kg/day, p.o. for 3 days) on expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), Fas, Fas ligand (FasL), and cleaved caspase-3 in myocardium from lean and ob/ob mice. (a) Representative gel blots of TNF-α, IL-6, Fas, FasL, cleaved caspase-3 and α-Tubulin (as loading control) using specific antibodies. (b) TNF-α. |
|
S1119 |
Cabozantinib (BMS-907351)Cabozantinib (XL184, BMS-907351)是一种有效的VEGFR2抑制剂,在无细胞试验中IC50为0.035 nM,也能有效抑制c-Met、 Ret、 Kit、Flt-1/3/4、Tie2和AXL,IC50分别为1.3 nM,4 nM,4.6 nM,12 nM/11.3 nM/6 nM,14.3 nM 和 7 nM。Cabozantinib 在结肠癌细胞中可通过AKT/GSK-3β/NF-κB信号通路诱导PUMA依赖的凋亡。 |
![]() ![]() Effects of AXL inhibitors on induction of pAKT and rescue of pERK following AXL overexpression. R428, 500 nmol/L; XL184, 3 umol/L; XL880, 100 nmol/L; in the presence or absence of 2 umol/L PLX4720. shAXL is a positive control.
|
|
S1490 |
Ponatinib (AP24534)Ponatinib (AP24534)是一种新型有效的多靶点抑制剂,在无细胞试验中作用于Abl,PDGFRα,VEGFR2,FGFR1和Src,IC50分别为0.37 nM,1.1 nM,1.5 nM,2.2 nM和5.4 nM。Ponatinib (AP24534)可抑制自噬。 |
![]() ![]()
RCH-ACV cells were treated with ponatinib(50 nM), PCI-32765(50 nM), or BMS-599626(500 nM) over a time course, and whole-cell extracts were subjected to immunoblot analysis for total or phospho-AKT.
|
|
S6870New |
NingetinibNingetinib (CT-053, DE-120, CT053PTSA)是一种有效的、可口服的 tyrosine kinase,对 c-Met、VEGFR2 和 Axl 的IC50值分别为6.7 nM、1.9 nM和 <1.0 nM。Ningetinib 表现出了抗肿瘤的活性。 |
||
S9621New |
Donafenib (Sorafenib D3)Donafenib (Sorafenib D3, Bay 43-9006 D3, CM-4307)是氘标记的Sorafenib。Sorafenib 是一种多激酶的抑制剂,对 Raf-1、mVEGFR-2、mVEGFR-3 和 B-RAF 的抑制作用对应的IC50值分别为6 nM、15 nM、20 nM和22 nM。 |
||
S7688New |
Ki20227Ki20227 是一种口服活性的 c-Fms tyrosine kinase(CSF1R) 的高选择性抑制剂,对 c-Fms、vascular endothelial growth factor receptor-2 (KDR/VEGFR-2)、stem cell factor receptor (c-Kit) 和 platelet-derived growth factor receptor beta (PDGFRβ) 的IC50值为2 nM、12 nM、451 nM和217 nM。 |
||
S6843New |
X-82 (Vorolanib)X-82 (Vorolanib, CM082)是一种口服的 vascular endothelial growth factor receptor (VEGFR) 和 platelet-derived growth factor receptor (PDGFR) 的多激酶双重抑制剂,并具有抗血管生成和抗肿瘤的活性。 |
||
S0765New |
MAZ51MAZ51 是一种选择性的 vascular endothelial growth factor receptor (VEGFR)-3 (Flt-4) tyrosine kinase 的有效抑制剂。MAZ51 通过 Akt/GSK3β 的磷酸化和 RhoA 的激活来诱导神经胶质瘤细胞的细胞圆缩和G2/M细胞周期停滞。 MAZ51 可抑制多种非VEGFR-3表达肿瘤细胞的增殖并诱导其凋亡。 |
||
S0504New |
SU14813SU14813 (SU 014813)是一种多受体 tyrosine kinase 的抑制剂,对于 VEGFR2、VEGFR1、PDGFRβ 和 Kit (c-Kit) 的IC50值分别为50 nM,2 nM,4 nM和15 nM。SU14813 具有强大的抗血管生成和抗肿瘤活性。 |
||
S0487New |
SulfatinibSulfatinib (HMPL-012, Sufatinib, Surfatinib)是一种有效的、具有高度选择性的 tyrosine kinase 的抑制剂,对于 VEGFR1、VEGFR2、VEGFR3、FGFR1 和 CSF1R 的IC50值分别为2 nM、24 nM、1 nM、15 nM和4 nM。Sulfatinib 在针对晚期NET患者的实验中显示出令人鼓舞的抗肿瘤活性和可控毒性。 |
||
S0377New |
CS-2660 (JNJ-38158471)CS-2660 (JNJ-38158471) 是一种耐受性良好的、口服有效的、高选择性的 VEGFR-2 抑制剂,IC50值为40 nM。CS-2660(JNJ-38158471)还抑制紧密相关的酪氨酸激酶,如 Ret (c-RET) 和 Kit (c-Kit),IC50为180 nM和500 nM,但无明显活性 (>1 microM) 针对VEGFR-1和VEGFR-3。 |
||
S0278New |
SU5614SU5614 (Chloro-SU5416, Chloro-Semaxanib) 是一种小分子 receptor tyrosine kinases (RTK) 的抑制剂,对 VEGFR-2、c-kit 以及野生型和突变型 FLT3 均有抑制作用。SU5614 可减少细胞增殖并诱导凋亡。 |
||
S0290New |
SU5204SU5204 是一种酪氨酸激酶抑制剂,对 FLK-1 (VEGFR-2) 和 HER2 的IC50值分别为4 μM和51.5 μM。 |
||
S6808New |
SU5205SU5205是 VEGF receptor 2 (VEGFR2/FLK-1) 的抑制剂,IC50为9.6 µM。 |
||
S6809New |
SU5214SU5214是 VEGF receptor 2 (VEGFR2/FLK-1) 和 EGFR 的抑制剂,对应的IC50值分别为14.8 µM 和 36.7 µM。 |
||
S6514New |
SU5408SU5408 (VEGFR2 Kinase Inhibitor I)是一种有效、选择性 VEGFR2 Kinase抑制剂,IC50为70 nM。 |
||
S6764New |
TAS-115TAS-115 is a unique VEGFR/Met (c-Met)-targeted inhibitor with IC50 of 30nM and 32nM for rVEGFR2 and rMet (c-Met), respectively. |
||
S2211New |
AG-13958AG-13958 (AG-013958)是VEGFR酪氨酸激酶抑制剂,在临床开发中发现ST给药可治疗与年龄相关性黄斑变性(AMD)的脉络膜新生血管生成。 |
||
S1005 |
AxitinibAxitinib (AG 013736)是一种多靶点抑制剂,作用于 VEGFR1,VEGFR2,VEGFR3,PDGFRβ和c-Kit,在猪主动脉内皮细胞中IC50分别为0.1 nM,0.2 nM,0.1-0.3 nM,1.6 nM和1.7 nM。 |
![]() ![]() Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids. |
|
S1111 |
Foretinib (GSK1363089)Foretinib (GSK1363089, EXEL-2880, XL-880) 是一种ATP竞争性的HGFR和VEGFR抑制剂,对Met (c-Met)和KDR作用最强,在无细胞试验中IC50分别为0.4 nM和0.9 nM。对Ron, Flt-1/3/4, Kit (c-Kit), PDGFRα/β和Tie-2作用效果稍弱,对FGFR1和EGFR几乎没有抑制活性。Phase 2。 |
![]() ![]() c-MET/RON inhibitors restore sensitivity to lapatinib in SK-BR-3-LR cells. Cell growth was determined using the sulforhodamine B assay. The concentration used was 0.1 uM for crizotinib, MGCD-265, XL880, sunitinib, dasatinib, and TAE-684I. The phosphorylation of HER2, AKT and ERK1/2 was determined by Western blotting.
|
|
S1046 |
Vandetanib (ZD6474)Vandetanib (ZD6474) 是一种有效的 VEGFR2 抑制剂,在无细胞试验中IC50为40 nM。同时,也抑制VEGFR3和EGFR,IC50分别为110 nM 和500 nM。对PDGFRβ, Flt-1, Tie-2 和FGFR1作用效果不大,IC50为 1.1-3.6 μM, 对MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt 和 IGF-1R几乎没有作用效果,IC50>10 μM。Vandetanib (ZD6474) 可增加凋亡并通过提高 reactive oxygen species (ROS) 的水平来诱导自噬。 |
![]() ![]() Vandetanib reduced extracellular nitrite levels in endothelial cells. MS1 endothelial cells (ECs) were incubated with 1 mol/L of vandetanib or matched vehicle (dimethyl sulfoxide [DMSO]), 50 ng/mL of vascular endothelial growth factor (VEGF) or matched vehicle (PBS; 0.5 hours), and L-arginine and soluble N-ethylmaleamide sensitive factor attachment protein (SNAP) added (1.5 hours). Vandetanib lowered nitrite levels in MS1 Ecs (*P0.0003). VEGF was used a positive control and increased nitrite levels (**P0.02). These findings indicate that vandetanib lowered endothelial cell NO levels. |
|
S1010 |
Nintedanib (BIBF 1120)Nintedanib (BIBF 1120, Intedanib, Vargatef, Ofev) 尼达尼布是一种有效的三重血管激酶抑制剂,作用于VEGFR1/2/3, FGFR1/2/3和PDGFRα/β,在无细胞试验中IC50分别为34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM和59 nM/65 nM。Phase 3。 |
![]() ![]() Effect of BIBF 1120 on the accumulation of doxorubicin (Dox) and rhodamine 123. The accumulations of doxorubicin a, b and rhodamine 123 c, d were measured by flow cytometric analysis as described in "Materials and Methods". The results are presented as fold change in fluorescence intensity relative to control MDR cells. Columns, means of triplicate determinations; bars, SDs. **P<0.01 versus control group |
|
S1178 |
Regorafenib (BAY 73-4506)Regorafenib (BAY 73-4506, Fluoro-Sorafenib, Resihance, Stivarga) 是一个多靶点抑制剂,作用于VEGFR1,VEGFR2,VEGFR3,PDGFR-β,Kit (c-Kit),RET (c-RET)和Raf-1,在无细胞试验中IC50分别是13 nM,4.2 nM,46 nM,22 nM,7 nM,1.5 nM和2.5 nM。Regorafenib 可诱导自噬。 |
![]() ![]() Hepatoma cells 24 h after plating were treated with vehicle (DMSO), regorafenib (REGO, 0.5 µM), PDE5 inhibitor (sildenafil, 2 µM); or the drugs in combination. 24 hours after treatment cells were isolated and viability determined by trypan blue (n=3, SEM). *P 0.05
|
|
S1035 |
Pazopanib HCl (GW786034 HCl)Pazopanib HCl (GW786034 HCl)是一种新型多靶点抑制剂,作用于VEGFR1,VEGFR2,VEGFR3,PDGFR,FGFR,c-Kit和c-fms,在无细胞试验中IC50分别是10 nM,30 nM,47 nM,84 nM,74 nM,140 nM和146 nM。Pazopanib 可诱导自噬II型细胞死亡。 |
![]() ![]() Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).
|
|
S1017 |
Cediranib (AZD2171)Cediranib (AZD2171, NSC-732208)是一种高效的VEGFR(KDR)抑制剂,IC50为<1 nM,同时也抑制Flt1/4,IC50为5 nM/≤3 nM,此外对c-Kit和PDGFRβ也具有相似的抑制活性,对VEGFR的选择性比PDGFR-α, CSF-1R和Flt3分别高36倍, 110倍 和1000倍以上。Cediranib (AZD2171)可诱导自噬小体累积。Phase 3。 |
![]() ![]() Western blots of EZH2 expression in A549, HCC461, and HCC4006 cells upon treatment with different doses of VEGFR-2-inhibitor AZD2171 (0, 5 and 10 nM). AZD2171 decreased the expression of EZH2 in HCC4006 and HCC461 cells expressing VEGFR-2 in a dose-dependent manner but did not do so in A549 cells lacking expression of VEGFR-2.
|
|
S1264 |
PD173074PD173074 是一种有效的FGFR1抑制剂,在无细胞试验中IC50约为25 nM,也能抑制VEGFR2,IC50为100-200 nM,作用于FGFR1比作用于PDGFR和c-Src选择性高1000倍左右。PD173074 可在胃癌细胞中抑制增殖并促进凋亡。 |
![]() ![]() FGFR inhibitors block signaling in FGFR2-fusion-expressing cells. Activation of FGFR2 and MAPK by FGFR2-AHCYL1 and its suppression by FGFR inhibitors. Lysates from NIH3T3 cells expressing FGFR2-AHCYL1 or EZR-ROS1 (control) treated with vehicle (DMSO), 0.2 and 1 uM BGJ398, and 0.2 and 1 uM PD173074 were immunoblotted with the relevant antibodies. β-Actin was used as a loading control.
|
|
S1018 |
Dovitinib (TKI-258)Dovitinib (TKI-258, CHIR-258)是一种多靶点的RTK抑制剂,在无细胞试验中对III型(FLT3/c-Kit)作用最强,IC50为1 nM/2 nM,同时也作用于IV类(FGFR1/3)和V类(VEGFR1-4) RTKs,IC50为8-13 nM,但对InsR,EGFR,c-Met,EphA2,Tie2,IGF-1R和HER2作用较弱。Phase 4。 |
![]() ![]()
Orthotopic xenografts of HNSCC cell lines (A) SCC-1 and (B) OSC-19 were treated with dovitinib (20 mg/kg/day). In addition, the OSC-19 xenografts were treated with +/ radiation therapy. Marker, mean for triplicate; bars, SE. Statistical significance by unpaired t-test, p < 0.05. |
|
S1003 |
Linifanib (ABT-869)Linifanib (ABT-869, AL39324, RG3635)是一种新型有效的ATP竞争性VEGFR/PDGFR抑制剂,作用于KDR,CSF-1R,Flt-1/3和PDGFRβ,其IC50分别为4 nM,3 nM,3 nM/4 nM和66 nM,对突变激酶依赖性癌细胞(即FLT3)最有效。Linifanib (ABT-869) 可诱导自噬和凋亡。Phase 3。 |
![]() ![]() (B and C) KMCH-1 cells were plated alone (monoculture) or together with PDGF-BB-secreting LX-2 cells (co-culture) in a transwell insert co-culture system (KMCH-1 cells in the bottom wells and LX-2 cells in the inserts; 1:1 ratio) for 2 days. Cells were treated as indicated with vehicle, rhTRAIL (10 ng/ml for 6 h on day 2), rhTRAIL plus imatinib [rhTRAIL:10 ng/ml for 6 h on day 2; Imatinib: 5 μmol/L for 24 h (day2)], or rhTRAIL plus linifanib [rhTRAIL: 10 ng/ml for 6 h on day 2; Linifanib:0.5 μmol/L for 24 h (day2)]. After rhTRAIL treatment for 6 h,KMCH-1 cells were analysed for apoptotic nuclear morphology by DAPI-staining (B) and for DNA fragmentation by transferasemediated dUTP nick end labelling assay (C) with quantification of apoptotic nuclei by fluorescence microscopy. |
|
S1101 |
Vatalanib (PTK787) 2HClVatalanib 2HCl (PTK787, ZK 222584, cpg-79787) 是一种VEGFR2/KDR抑制剂,无细胞试验中IC50为37 nM,对VEGFR1/Flt-1作用稍弱,是VEGFR3/Flt-4抑制作用的18倍。Phase 3。 |
![]() ![]() (Aa-Ja) A single row of BTs on the intact fin and stump after 6-14 dot with PTK787 and 4-12 dot with T. Small BTs appear in the fin regenerate after 8 dot with PTK787 and 6 dot with T (Da,Ea). A small BT cluster appears on the regenerate after 14 dot with PTK787 and 12 dot with T (Ga,Ha). (Ab-Jb) After 4 dot with T, BTs develop on the regenerate, stump and intact fin and continue to grow from 6-12 dot. (Jb) After 12 dot, the blood vessel network of T-treated females is similar to that of males. (Ac-Jc) PTK787-treated females do not possess BTs. (Aa-Ja,Ac-Jc) Neo-angiogenesis and regenerative outgrowth are inhibited in all PTK787-treated females. (Ad-Jd) System water controls regenerate normally and do not grow BTs. B.F., brightfield. Fli, fli1a:EGFP (green). KR21 (red) outlines the BTs. White vertical lines indicate the amputation plane. Scale bar: 100 um.
|
|
S2161 |
RAF265 (CHIR-265)RAF265 (CHIR-265)是一种有效的选择性C-Raf/B-Raf/B-Raf V600E抑制剂,IC50为3-60 nM,对VEGFR2磷酸化表现出有效的抑制作用,无细胞试验中EC50为30 nM。RAF265 (CHIR-265)可诱导细胞周期阻滞和凋亡。Phase 2。 |
![]() ![]() Immunoblots showing levels of phospho-MEK (p-MEK), total MEK (t-MEK), phospho-ERK1/2 (p-ERK1/2) and total ERK1/2 (t-ERK1/2) in A375 cells transduced with a retrovirus expressing BRAFV600E, BRAFV600E/L505H, BRAFV600E/F516G or BRAFV600E/T529N and treated with increasing doses of RAF265. α-tubulin (TUBA) was monitored as a loading control. |
|
S1207 |
Tivozanib (AV-951)Tivozanib (AV-951, KRN-951)是一种有效的,选择性VEGFR抑制剂,作用于VEGFR1/2/3时,IC50分别为0.21 nM/0.16 nM/0.24 nM,也抑制PDGFR和c-Kit,作用于FGFR-1, Flt3, c-Met EGFR和IGF-1R活性较弱。Phase 3。 |
![]() ![]() On-chip angiogenesis assay. Fluorescence imaging of Tg(fli1a:EGFP) embryos at 64 hpf. Transgenic embryos were arrayed and immobilized at 16 hpf and continuously perfused with E3 media containing vehicle control (dimethyl sulfoxide) or selected small-molecule antiangiogenic drugs (Sunitinib and Tivozanib). Right panel: microscopic visualization of patterns of ISV. White arrows: normal ISV growth; blue arrows: partial ISV growth inhibition; and red arrows; complete ISV growth inhibition.
|
|
S1032 |
Motesanib Diphosphate (AMG-706)Motesanib Diphosphate (AMG-706)是一种有效的ATP竞争性的VEGFR1/2/3抑制剂,IC50分别为2 nM/3 nM/6 nM;对Kit (c-Kit)具有相似的抑制活性,对VEGFR选择性比PDGFR和Ret高10倍。Phase 3。 |
![]() ![]() Immunofluorescence staining of choroidal neovascularization (CNV) lesions 14 days after laser photocoagulation. Choroidal flat mounts were fluorescently labeled with F-actin-specific marker phalloidin (green channel), endothelial cell marker CD34 (red channel), and nuclear marker DAPI (blue channel). CNV lesions in topical vehicle-treated eye (A, C, E and G) and topical motesanib-treated eye (B, D, F and H). The scale bar represents 100 um.
|
|
S1164 |
Lenvatinib (E7080)Lenvatinib (E7080)是一种多靶点抑制剂,无细胞试验中,作用于VEGFR2(KDR)/VEGFR3(Flt-4)最有效,IC50为4 nM/5.2 nM,对VEGFR1/Flt-1作用效果稍弱,作用于VEGFR2/3比作用于FGFR1, PDGFRα/β选择性高10倍左右。Lenvatinib (E7080) 也是FGFR1-4、PDGFR、Kit (c-Kit)和RET (c-RET)的抑制剂,并具有强效的抗肿瘤活性。Phase 3。 |
![]() ![]() Dot Plot Distribution of Live, Preapoptotic and Apoptotic Cells after Administration of DuP-697 and E7080 Combination.
|
|
S1084 |
Brivanib (BMS-540215)Brivanib (BMS-540215)是一种ATP竞争性的VEGFR2抑制剂,IC50为25 nM,对VEGFR-1和FGFR-1抑制作用适中,但比作用于PDGFR-β效果强240多倍。Phase 3。 |
![]() ![]() For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Brivanib by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 μM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.
|
|
S1361 |
MGCD-265 analogMGCD-265是一种有效的,多靶点,及ATP竞争性的c-Met和VEGFR1/2/3抑制剂,IC50分别为1 nM, 3 nM/3 nM/4 nM,也抑制Ron和Tie2。Phase 1/2。 |
![]() ![]() c-MET/RON inhibitors restore sensitivity to lapatinib in SK-BR-3-LR cells. The concentration used was 0.1 uM for crizotinib, MGCD-265, XL880, sunitinib, dasatinib, TAE-684, and RON inhibitor I. Columns, means; bars, SEMs (n = 3). The phosphorylation of HER2, AKT and ERK1/2 was determined by Western blotting.
|
|
S1486 |
AEE788 (NVP-AEE788)AEE788 (NVP-AEE788)是一种有效的EGFR和HER2/ErbB2抑制剂,IC50分别为2 nM和6 nM,对VEGFR2/KDR, c-Abl, c-Src,和Flt-1作用效果稍弱,对Ins-R, IGF-1R, PKCα和CDK1没有抑制作用。Phase 1/2。 |
![]() ![]() EGFR-SGLT1 interaction is irresponsive to modulators of EGFR’s tyrosine kinase. A: Immunoprecipitation coupled Western blot analysis ofinteractionsbetween EGFR-HA and SGLT1-FlaginHEK293 cells treatedwith EGF or AEE788. EGFR, total EGFR; pEGFR, phosphorylated EGFR; IP, immunoprecipitation; IB, immunoblot. Input, expression levels of indicated exogenous proteinsin HEK293 whole celllysates used for the IP. |
|
S1181 |
ENMD-2076ENMD-2076 选择性地作用于 Aurora A 和 Flt3,IC50分别为14 nM和1.86 nM,作用于Aurora A比作用于Aurora B选择性高25倍,对RET、SRC、NTRK1/TRKA、CSF1R/FMS、VEGFR2/KDR、FGFR和PDGFRα作用效果稍弱。ENMD-2076 可抑制各种人类实体瘤和造血癌细胞系的生长,其IC50值为0.025至0.7μM,可诱导凋亡和G2/M期停滞。Phase 2。 |
![]() ![]() Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of ENMD-2076.
|
|
S1220 |
OSI-930OSI-930是一种有效的Kit (c-Kit), KDR和CSF-1R抑制剂,IC50分别为80 nM, 9 nM和15 nM,对Flt-1, c-Raf和Lck具有适度的抑制活性,对PDGFRα/β, Flt-3和Abl抑制活性较弱。Phase 1。 |
![]() ![]() RE-luc2P-HEK293 cells were pretreated with 1uM OSI-930 (green), 20uM TBB (blue), 10uM CKI-7 (purple), or 10uM H-89 (orange) for 16 h and infected with Y. enterocolitica WA or Y. pestis Ind195 at MOI 1 and 20, respectively, for 1 h. Following stimulation with 10 ng/ml TNF-α at 5 h post-infection, luciferase activity was measured 24 h post-infection. Results were determined from two independent experiments performed in triplicate. A"*" denotes that the % NF-κβ inhibition using the inhibitors was significantly different (p<0.05) compared to the no drug control (black). The relative NF-κB inhibition by Yersinia infection was determined as a percentage of luciferase activity in bacteria-infected cells relative to luciferase activity in bacteria-free control cells.
|
|
S1171 |
CYC116CYC116是一种有效的Aurora A/B抑制剂,Ki为8.0 nM/9.2 nM,对VEGFR2(Ki为44 nM)作用稍弱,比作用于CDKs效果强50倍,对PKA, Akt/PKB, PKC没有活性,对GSK-3α/β, CK2, Plk1和SAPK2A.没有抑制效果。Phase 1。 |
![]() ![]() Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of CYC116.
|
|
S1363 |
Ki8751Ki8751是一种有效的,选择性的VEGFR2抑制剂,IC50为0.9 nM,作用于VEGFR2比作用于c-Kit, PDGFRα和FGFR-2选择性高40倍以上,对EGFR, HGFR和InsR没有抑制活性。 |
![]() ![]()
Effect of select kinase inhibitors on DF508-CFTR maturation analyzed by immunoblotting. 293MSR-GT cells stably expressing DF508-CFTR were treated with 15 uM kinase inhibitors or 0.3% DMSO (vehicle control), as indicated, grown at 37 °C for 48 h, and the appearance of the mature protein, band C, monitored
by immunoblotting with anti-CFTR antibodies. Band B represents the immature protein. DMSO represents vehicle-alone control, 27 °C represents temperature rescue of F508-CFTR at 27 °C, 37 °C represents untreated DF508-CFTR control, and WT represents WT-CFTR. Top panels depict the anti-CFTR immunoblot and bottom panels depict actin (loading) control. ** represents cellular toxicity.
|
|
S2231 |
TelatinibTelatinib (BAY 57-9352) 是一种有效的VEGFR2/3, c-Kit和PDGFRα抑制剂,IC50分别为6 nM/4 nM, 1 nM和15 nM。Phase 2。 |
![]() ![]() |
|
S2622 |
PP121PP121是一种作用于PDGFR, Hck, mTOR, VEGFR2, Src和Abl的多靶点抑制剂,IC50分别为2 nM, 8 nM, 10 nM, 12 nM, 14 nM和18 nM,也抑制DNA-PK,IC50为60 nM。 |
![]() ![]() PP121 induces apoptosis in ATC cells. CAL62 cells were treated with PP121 at the indicated concentrations for 48 h, followed by PI staining. The nuclei were stained with Hoechst and analyzed using a fluorescent microscope. The representative images are shown.
|
|
S3012 |
PazopanibPazopanib (GW786034) 是一种新型多靶点的VEGFR1,VEGFR2,VEGFR3,PDGFR,FGFR,c-Kit 和 c-Fms/CSF1R抑制剂,无细胞试验中IC50分别为10 nM,30 nM,47 nM,84 nM,74 nM,140 nM 和 146 nM。Pazopanib 可诱导 cathepsin B 的活化和自噬。 |
![]() ![]() Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).
|
|
S1557 |
KRN 633KRN 633是一种ATP竞争性的VEGFR1/2/3抑制剂,IC50为170 nM/160 nM/125 nM,微弱抑制PDGFR-α/β和c-Kit,对细胞中FGFR-1, EGFR和c-Met的磷酸化没有抑制作用。 |
![]() ![]() Inhibited migration of hNSCs toward HeLa cells with the treatment of KRN633, a VEGFR2 inhibitor. The cultured hNSCs were treated with KRN633 for 6 h. After that, the transwell migration assay was performed as described above. The number of migrated cells was counted and the results were presented as means ± SD. Magnification,× 200. *P < 0.05 vs. KRN633 non-treated
GESTECs. (A) Migrated HB1.F3.CD cells. (B) Migrated HB1.F3.CD.IFN-β cells.
|
|
S2842 |
SAR131675SAR131675是一种VEGFR3抑制剂,无细胞试验中IC50/Ki为23 nM/12 nM,作用于VEGFR3比作用于VEGFR1/2选择性高50和10倍,对Akt1, CDKs, PLK1, EGFR, IGF-1R, c-Met, Flt2等几乎没有作用活性。 |
![]() ![]() Blockade of IPC-induced ischemic tolerance by the VEGFR-3 inhibitor SAR131675. (A) Representative images of FJ-stained brain sections from sham + SARH (i), sham-IPC + SI + Veh (ii), IPC + SI + Veh (iii) and IPC + SI + SARH (iv) groups. Note that there were more degenerated neurons in the IPC + SI + SARH group receiving SAR131675 of 50 mg/kg as an initial dose than in the IPC + SI + Veh group. Scale bar = 50 μm. (B) The quantitative analysis shows the number of FJ-positive degenerated neurons in the CA1 subregion of the different treatment groups including the IPC + SI + SARL group receiving SAR131675 of 25 mg/kg as an initial dose. Data are presented as the mean ± SEM; # p < 0.05 compared with the sham-IPC + SI + Veh group; *p < 0.05 compared with the IPC + SI + Veh group. (C) Representative images of NeuN immunofluorescence in the sham + SARH (i), sham-IPC + SI + Veh (ii), IPC + SI + Veh (iii) and IPC + SI + SARH (iv) groups. Note that NeuN-immunofluorescence in the IPC + SI + SARH group was reduced compared with the IPC + SI + Veh group. Scale bar = 50 μm. (D) The quantitative analysis shows the number of NeuN-positive intact pyramidal neurons in the CA1 subregion for the different treatment groups. Data are presented as the mean ± SEM; #p < 0.05 compared with the sham-IPC + SI + Veh group; *p < 0.05 compared with the IPC + SI + Veh group. |
|
S2201 |
BMS-794833BMS-794833是一种有效的,ATP竞争性Met (c-Met)/VEGFR2抑制剂,IC50为1.7 nM/15 nM,也抑制Ron, Axl和Flt3,IC50低于3 nM;是BMS-817378的前体药物。 Phase 1。 |
||
S7397 |
SorafenibSorafenib (BAY 43-9006) 是Raf-1和B-Raf的多重激酶抑制剂,无细胞试验中IC50分别为6 nM和22 nM。Sorafenib 还可抑制VEGFR-2、VEGFR-3、PDGFR-β、Flt-3和c-KIT,对应的IC50值分别为90 nM、20 nM、57 nM、59 nM和68 nM。Sorafenib 可诱导autophagy、apoptosis并激活ferroptosis,Sorafenib 具有抗肿瘤活性。 |
![]() ![]() Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.
|
|
S4001 |
Cabozantinib malate (XL184)Cabozantinib malate (XL184)是Cabozantinib的苹果酸盐,是有效的VEGFR2抑制剂,IC50为0.035 nM,也抑制c-Met, RET (c-RET), Kit (c-Kit), Flt-1/3/4, Tie2和AXL,无细胞试验中IC50分别为1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM和7 nM。Cabozantinib malate (XL184)可诱导细胞凋亡。 |
![]() ![]() Effects of AXL inhibitors on induction of pAKT and rescue of pERK following AXL overexpression. R428, 500 nmol/L; XL184, 3 umol/L; XL880, 100 nmol/L; in the presence or absence of 2 umol/L PLX4720. shAXL is a positive control.
|
|
S1138 |
Brivanib Alaninate (BMS-582664)Brivanib Alaninate (BMS-582664)是BMS-540215的前体药物,是一种ATP竞争性的VEGFR2抑制剂,IC50为25 nM。 |
![]() ![]() |
|
S2859 |
Golvatinib (E7050)Golvatinib (E7050)是c-Met和VEGFR-2双重抑制剂,IC50分别为14 nM和16 nM,不抑制bFGF刺激的HUVEC生长(浓度高达1000 nM)。Phase 1/2。 |
![]() ![]() PC-9/LMC-GR cells (2 × 105 cells/well) were incubated in 6-well plates with various concentrations of gefitinib with or without crizotinib (1 μmol/L) or golvatinib (1 μmol/L) for 1 hour. Cell lysate were obtained and subjected to immunoblotting with antibodies toward the indicated molecules.
|
|
S2845 |
Semaxanib (SU5416)Semaxanib (SU5416)是一种有效的,选择性的VEGFR(Flk-1/KDR)抑制剂,IC50为1.23 μM,作用于VEGFR比作用于PDGFRβ选择性高20倍,对EGFR, InsR和FGFR没有作用活性。Phase 3。 |
![]() ![]() Injected tumor cells move to the tail via blood vessels. Tg (flil1:egfp) embryos at 20 hpf were treated with 2 μM SU5416 for 1 hr (+SU5416) to inhibit vasculogenesis24; the control fish were treated with 0.02% DMSO for 1 hr (-SU5416). After 1 hr, SU5416 or DMSO was washed out by changing fish media. At 48 hpf, tfRFP-B16 cells were injected into the pericardium cavity of fish. Representative images show that tumor cells moved to the tail in a drug-free larva, while no tumor cells moved to the tail in a drug-treated larva after new vessels were inhibited by SU5416. Insets are enlarged images from each corresponding tip of the tail indicated by white arrows. Dashed white lines mark extravasated tumor cells at 12 hpi. Vessels are green and tumor cells are red. –SU5416, 6 other larvae exhibit similar behaviors; +SU5416, 3 other larvae exhibit similar behaviors. Scale bars, 500 μm. Insets, 100 μm.
|
|
S2897 |
ZM 306416ZM 306416 (CB 676475) 是一种VEGFR(Flt和KDR)抑制剂,作用于VEGFR1,IC50为0.33 μM,也抑制EGFR,IC50为<10 nM。 |
![]() ![]() Panels D-F show morphological changes of RBEC cells due to Sema3A treatment. RBECs were fixed after the indicated treatment and stained with phalloidin conjugated with rhodamine (red color) and counter stained with DAPI (blue color). F-actin stress fibres are very clear in untreated cells (D). Sema3A treatment caused disruption of F-actin inside the cells. Densely packed bundles of cortical actin filaments started to appear along cell membranes (arrows) over the course of treatment with Sema3A. Antibodies and inhibitors against receptors of Sema3A were pre-incubated with the cells for 15 min before the addition of Sema3A. Antibodies to VEGFR1 and NRP2 (panel E) and the inhibitor Zm 306416 (selective to VEGFR1, panel F) were effective in ameliorating the effect of Sema3A. Scale bar=20 μm. |
|
S2896 |
ZM 323881 HClZM 323881 HCl是一种有效的,选择性的VEGFR2抑制剂,IC50为<2 nM,对VEGFR1, PDGFRβ, FGFR1, EGFR和ErbB2几乎没有活性。 |
![]() ![]() (A) Fluorescence microscopic analysis of Hoechst 33342 staining of NCIH460 and NCI-H460/MX20 cells. Cells were treated as described in ‘2. Materials and Methods’. Scale bar, 10 μm. (B) Effects of ZM323881 on intracellular accumulation of [3H]-mitoxantrone in NCI-H460 and NCI-H460/MX20 cells. (C) Efflux of [3H]-mitoxantrone in the absence and presence of inhibitors in NCI-H460 cells. (D) Efflux of [3H]-mitoxantrone in the absence and presence of inhibitors in NCI-H460/MX20 cells.
|
|
S2018 |
ENMD-2076 L-(+)-Tartaric acidENMD-2076 L-(+)-Tartaric acid 是ENMD-2076的酒石酸,选择性作用于Aurora A和VEGFR(Flt3),IC50分别为14 nM和1.86 nM,作用于Aurora A比作用于Aurora B选择性高25倍,对VEGFR2/KDR和VEGFR3, FGFR1和FGFR2和PDGFRα作用效果稍弱。Phase 2。 |
![]() ![]() Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of ENMD-2076.
|
|
S7057 |
LY2874455LY2874455是一个泛FGFR的抑制剂,对FGFR1,FGFR2, FGFR3, 和FGFR4的IC50值分别为2.8 nM, 2.6 nM, 6.4 nM,以及6 nM。并且也能抑制VEGFR2的活性,IC50为7 nM。Phase 1。 |
![]() ![]() A: Overall structure of LY2874455/FGFR4 complex. B: The diagram of LY2874455. C: Fo-Fc omit map of LY2874455 in the FGFR4/LY2874455 complex. The electron density is superimposed with the final model. D: The DFG motif conformation of FGFR4. Active ApoFGFR4 DFG-in conformation is shown in blue (PDB: 4QQT); FGFR4/Ponatinib DFG-out conformation is shown in yellow (PDB: 4UXQ); FGFR4/BLU9931 DFG-in conformation is shown in pink (PDB: 4XCU); FGFR4/LY2874455 DFG-in conformation is shown in grey (this work). LY2874455 is highlighted in brown.
|
|
S8189 |
BAW2881 (NVP-BAW2881)BAW2881 (NVP-BAW2881)是一种新型的VEGFR酪氨酸激酶抑制剂。在1.0-4.3 nM浓度下能有效地抑制VEGFR1-3;在45-72 nM的浓度下,抑制PDGFRβ, c-Kit和RET (c-RET)。 |
||
S6520 |
WHI-P180WHI-P180是多种激酶的抑制剂,对RET (c-RET)和KDR的IC50值分别为4.5 nM和66 nM。 |
||
S6543 |
ZD-4190ZD-4190是VEGF RTK抑制剂,对KDR和Flt-1的IC50值分别为29 ± 4 nM和708 ± 63 nM。 |
||
S6535 |
SU1498SU1498是KDR抑制剂,IC50为0.7 μM,可在内皮细胞中刺激磷酸化ERK1/2的累积。 |
||
S7667 |
SU5402SU5402是一种有效的多靶点受体激酶抑制剂,对VEGFR2,FGFR1,和PDGF-Rβ的IC50分别为20 nM,30 nM,和510 nM。 |
![]() ![]() Four FGFR inhibitors, namely PD-173074 (PD-74), PD-166866 (PD-66), SU5402 (SU54) and NVP-BGJ398 (BG-98), inhibit A673, SKNMC, POE, RDES and SKES Ewing cell growth in vitro in a dose-dependent manner, whereas normal cells (IMR90 fibroblasts) remained unaffected. PD-74 proved to be most effective in four out of five Ewing sarcoma cell lines tested. Cells were grown in 10% FBS conditions and cell proliferation was measured after 72 h using a Resazurin assay.
|
|
S8721 |
PDGFR inhibitor 1PDGFR inhibitor 1是一种具有口服活性的Kit (c-Kit)和PDGFR抑制剂,具有潜在的抗肿瘤活性。它还能抑制好几种其他激酶,包括VEGFR2、TIE2、PDGFR-beta和CSF1R,因此进而抑制肿瘤细胞的生长。 |
||
S7765 |
Dovitinib (TKI258) LactateDovitinib (TKI258, CHIR258) Lactate是Dovitinib的乳酸盐,Dovitinib是一种多靶点的PTK抑制剂,主要对第III类(FLT3/c-Kit)发挥作用,IC50为1 nM/2 nM,对第IV 类(FGFR1/3)和第V 类(VEGFR1-4) RTKs也有效,IC50为8-13 nM,对InsR,EGFR,c-Met,EphA2,Tie2,IGFR1 和HER2作用较差。Phase 4。 |
![]() ![]() (c) Percent survival for the AGS cancer cell line is shown with FGFR2 inhibitors of varying specificity. (d) The KatoIII diffuse gastric cancer cell line was treated with FGFR2 inhibitors of varying specificity. The Y-axis depicts percent survival versus the X-axis with log concentrations. In all panels, error bars represent standard error of the mean. The difference in percent cell survival between KatoIII and AGS cells was statistically significant (P <0.05) at the three highest concentrations of all drugs, except Brivanib which was only significant at the highest concentration. |
|
S5272 |
Toceranib phosphateToceranib phosphate (Palladia, SU11654), the phosphate salt of toceranib, is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family, including Flk-1/KDR, PDGFR, and Kit with Ki values of 6 nM and 5 nM for Flk-1/KDR and PDGFRβ, respectively. |
||
S5242 |
Cediranib MaleateCediranib Maleate (AZD-2171) is the maleate salt of Cediranib, which is a potent inhibitor of VEGFR with IC50 of <1 nM and also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM. |
||
S8188 |
BFH772BFH772是一种新型的、有效的、可口服的VEGFR2抑制剂,IC50为3 nM。 |
||
S5240 |
lenvatinib MesylateLenvatinib Mesylate 是一种合成、具有口服活性的 tyrosine kinase 的抑制剂,可抑制血管内皮生长因子受体(VEGFR1-3),成纤维细胞生长因子受体(FGFR1-4),血小板衍生生长因子受体(PDGFRα),干细胞因子受体(Kit (c-Kit)),并在转染过程中重新排列(RET (c-RET))。甲磺酸来伐替尼具有潜在的抗肿瘤活性。 |
||
S5667 |
Fruquintinib (HMPL-013)Fruquintinib (HMPL-013) is a small molecule inhibitor with strong potency and high selectivity against VEGFR family. It inhibits VEGFR 1, 2, 3, with IC50 values of 33 nM, 35 nM and 0.5 nM, respectively and shows only weak inhibition of RET, FGFR-1 and c-kit kinases. |
||
S8882 |
ODM-203ODM-203是FGFR 和 VEGFR的双重抑制剂,对重组FGFR1,FGFR2,FGFR3,FGFR4,VEGFR1,VEGFR2和VEGFR3的ic50分别为11 nM,16 nM,6 nM,35 nM,26 nM,9 nM,5 nM。 |
||
S8401 |
Erdafitinib (JNJ-42756493)Erdafitinib (JNJ-42756493)是有效的、具有选择性和口服生物活性的泛成纤维细胞生长因子受体FGFR抑制剂,具有潜在的抗肿瘤活性。Erdafitinib 也能结合RET (c-RET)、CSF-1R、PDGFR-α/PDGFR-β、FLT4、Kit (c-Kit)和VEGFR-2并可诱导细胞凋亡。 |
![]() ![]() E, Continuous ERK phosphorylation in FGFR inhibitor resistant cells under 24-hour treatment with 1 μmol/L BGJ398 assessed by immunoblotting. FGFR inhibitors: AZD4547, BGJ398, and JNJ-42756493 |
|
S6526 |
SKLB 610SKLB-610是一种多靶点的酪氨酸激酶 (tyrosine kinases)抑制剂。它对VEGFR2的抑制作用最为有效,是FGFR2和PDGFR的弱抑制剂。 |
||
S7781 |
SunitinibSunitinib (SU11248) 是一种多靶点 RTK 抑制剂,以VEGFR2(Flk-1)和PDGFRβ为靶点,IC50为80 nM 和 2 nM,对c-Kit也有抑制作用。Sunitinib 还是 IRE1α 的自磷酸化活性的剂量依赖性抑制剂。 舒尼替尼可诱导自噬和细胞凋亡。 |
![]() ![]() Sunitinib decreases FLT-3 and RET phosphor ylation but increases ERK phosphorylation in a time-dependent manner. H295R and SW13 cells were treated with sunitinib (10 nM) for various time points as indi-cated. Cell lysates were prepared and phospho-FLT-3, RET, and ERK levels were monitored by Western Blot-ting. Re-probing against FLT-3, RET, and ERK was done to ensure equal protein loading. |
|
S8573 |
Sitravatinib (MGCD516)Sitravatinib (MGCD516, MG-516)是一种新型的、靶向多种参与调节S180肉瘤细胞生长的RTKs的小分子抑制剂,包括c-Kit, PDGFRβ, PDGFRα, c-Met和Axl。 |
||
S7258 |
SKLB1002SKLB1002 是一种与ATP竞争的强效VEGFR2抑制剂,其IC50为32 nM. |
![]() ![]() Protein expressions of VEGFR2, p-VEGFR2, FAK, p-FAK, ERK, p-ERK and VE-cadherin in HCT116 cells with or without SKLB1002 treatment were determined by western blotting analysis. Representative data of three experiments are shown
|
|
S5793 |
Motesanib (AMG-706)Motesanib (AMG-706)是一种具有口服生物活性的受体酪氨酸激酶 (receptor tyrosine kinase)抑制剂,对VEGFR1, VEGFR2, VEGFR3, Kit, PDGFR和Ret的IC50值分别为2、3、6、8、84和59 nM。 |
||
S8696 |
2-D082-D08 (2',3',4'-trihydroxy flavone) 是一种具有细胞透性的蛋白类泛素化(protein sumoylation)抑制剂。它还能抑制Axl, IRAK4, ROS1, MLK4, GSK3β, RET (c-RET), KDR和PI3Kα,IC50分别为0.49, 3.9, 5.3, 9.8, 11, 11, 17和35 nM。 |
||
S6412 |
AltiratinibAltiratinib (DCC-2701) 是有效的TRK, Met (c-Met), TIE2和VEGFR2激酶抑制剂,对TRKA, B和C的IC50分别为0.9 nM, 4.6 nM和0.8 nM。它抑制Met (c-Met)和Met (c-Met)突变体的IC50范围为0.3-6 nM。 |
||
S4686 |
Vitamin EVitamin E (D-alpha-Tocopherol) 是一种脂溶性的维生素,具有有效的抗氧化特性。它是有效的过氧化氢自由基清除剂并在很多组织中,非竞争性地抑制环氧酶活性。同时通过抑制VEGF基因转录,抑制血管生成和肿瘤休眠。 |
||
S7003 |
AZD2932AZD2932 是一种有效的多靶点蛋白酪氨酸激酶抑制剂,对VEGFR-2,PDGFRβ,Flt-3,和 c-Kit 的 IC50 分别为 8 nM,4 nM,7 nM,和 9 nM。 |
||
S8726 |
Anlotinib (AL3818) dihydrochlorideAnlotinib (AL3818) 是一种高度有效的VEGFR2选择性抑制剂,IC50小于1 nM。它在临床试验中具有广谱性抗肿瘤潜力。稀释请用生理盐水,请勿用PBS稀释,可能产生沉淀。 |
||
S5234 |
Nintedanib Ethanesulfonate SaltNintedanib (Intedanib, BIBF 1120) is a small molecule tyrosine-kinase inhibitor with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β, respectively. |
||
S5077 |
Regorafenib MonohydrateRegorafenib (BAY-734506, Fluoro-sorafenib, Resihance, Stivarga) Monohydrate 是一种新型口服的多重激酶抑制剂,对VEGFR1、小鼠VEGFR2、小鼠VEGFR3、PDGFR-β、Kit (c-Kit)、RET (c-RET)、RAF-1、B-RAF和B-RAF(V600E)的IC50分别为13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM。 |
||
S2366 |
Taxifolin (Dihydroquercetin)Taxifolin(Dihydroquercetin)是一种二氢黄酮醇类,是一种黄酮类化合物。是I型VEGFR2 kinase的抑制剂。 |
||
A2003New |
Ramucirumab (anti-VEGFR2)Ramucirumab (anti-VEGFR2) 是IgG1类的单克隆抗体,可与 VEGF-R2 结合并阻止其激活,其阻断KDR与VEGF结合的 IC50 值为0.8 nM;MW: 143.6 KD。 |
||
A2006 |
Bevacizumab (anti-VEGF)Bevacizumab (anti-VEGF, Avastin) 是一种人源化的anti-VEGF单克隆抗体,是VEGF的抑制剂。可与所有人源VEGF-A亚型(和具有生物活性的蛋白水解片段)结合、中和。MW:149 KD。 |
![]() ![]() VEGFA expression in the indicated cells treated with or without bevacizumab or transfected with VEGFA or shVEGFA.
|
目录号 | 产品描述 | 文献引用 | 实验数据 |
---|---|---|---|
S1040 |
Sorafenib TosylateSorafenib Tosylate (Bay 43-9006) 是Raf-1和B-Raf的多重激酶抑制剂,无细胞试验中IC50分别为6 nM和22 nM。Sorafenib 还可抑制VEGFR-2、VEGFR-3、PDGFR-β、Flt-3和c-KIT,对应的IC50值分别为90 nM、20 nM、57 nM、59 nM和68 nM。Sorafenib Tosylate 可诱导autophagy、apoptosis并激活ferroptosis,并具有抗肿瘤活性。 |
![]() ![]()
Inhibition of breast cancer cell growth using sorafenib. MCF-7 breast cancer cells were treated with increasing concentrations of sorafenib for 5 days. Cell number was measured using a colorimetric growth assay (crystal violet stain) and expressed relative to DMSO treated control cells. |
|
S1042 |
Sunitinib MalateSunitinib Malate是一种多靶点RTK抑制剂,作用于VEGFR2 (Flk-1)和 PDGFRβ,在无细胞试验中IC50分别为80 nM 和2 nM,也会抑制c-Kit的活性。Sunitinib Malate 可有效地抑制 Ire1α 的自身磷酸化。Sunitinib Malate 可增加 death receptor 和 线粒体依赖的凋亡 mitochondrial-dependent apoptosis。 |
![]() ![]() Sunitinib decreases FLT-3 and RET phosphor ylation but increases ERK phosphorylation in a time-dependent manner. H295R and SW13 cells were treated with sunitinib (10 nM) for various time points as indi-cated. Cell lysates were prepared and phospho-FLT-3, RET, and ERK levels were monitored by Western Blot-ting. Re-probing against FLT-3, RET, and ERK was done to ensure equal protein loading. |
|
S1029 |
Lenalidomide (CC-5013)Lenalidomide (CC-5013)是一种TNF-α分泌抑制剂,在PBMCs中IC50为13 nM。Lenalidomide (CC-5013) 是 ubiquitin E3 ligase cereblon (CRBN) 的配体,它通过CRBN-CRL4泛素连接酶引起两个淋巴样转录因子IKZF1和IKZF3的选择性泛素化和降解。Lenalidomide 可促进 cleaved caspase-3 的表达、抑制 VEGF 的表达并诱导凋亡。 |
![]() ![]()
Effect of lenalidomide treatment (50 mg/kg/day, p.o. for 3 days) on expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), Fas, Fas ligand (FasL), and cleaved caspase-3 in myocardium from lean and ob/ob mice. (a) Representative gel blots of TNF-α, IL-6, Fas, FasL, cleaved caspase-3 and α-Tubulin (as loading control) using specific antibodies. (b) TNF-α. |
|
S1119 |
Cabozantinib (BMS-907351)Cabozantinib (XL184, BMS-907351)是一种有效的VEGFR2抑制剂,在无细胞试验中IC50为0.035 nM,也能有效抑制c-Met、 Ret、 Kit、Flt-1/3/4、Tie2和AXL,IC50分别为1.3 nM,4 nM,4.6 nM,12 nM/11.3 nM/6 nM,14.3 nM 和 7 nM。Cabozantinib 在结肠癌细胞中可通过AKT/GSK-3β/NF-κB信号通路诱导PUMA依赖的凋亡。 |
![]() ![]() Effects of AXL inhibitors on induction of pAKT and rescue of pERK following AXL overexpression. R428, 500 nmol/L; XL184, 3 umol/L; XL880, 100 nmol/L; in the presence or absence of 2 umol/L PLX4720. shAXL is a positive control.
|
|
S1490 |
Ponatinib (AP24534)Ponatinib (AP24534)是一种新型有效的多靶点抑制剂,在无细胞试验中作用于Abl,PDGFRα,VEGFR2,FGFR1和Src,IC50分别为0.37 nM,1.1 nM,1.5 nM,2.2 nM和5.4 nM。Ponatinib (AP24534)可抑制自噬。 |
![]() ![]()
RCH-ACV cells were treated with ponatinib(50 nM), PCI-32765(50 nM), or BMS-599626(500 nM) over a time course, and whole-cell extracts were subjected to immunoblot analysis for total or phospho-AKT.
|
|
S6870New |
NingetinibNingetinib (CT-053, DE-120, CT053PTSA)是一种有效的、可口服的 tyrosine kinase,对 c-Met、VEGFR2 和 Axl 的IC50值分别为6.7 nM、1.9 nM和 <1.0 nM。Ningetinib 表现出了抗肿瘤的活性。 |
||
S9621New |
Donafenib (Sorafenib D3)Donafenib (Sorafenib D3, Bay 43-9006 D3, CM-4307)是氘标记的Sorafenib。Sorafenib 是一种多激酶的抑制剂,对 Raf-1、mVEGFR-2、mVEGFR-3 和 B-RAF 的抑制作用对应的IC50值分别为6 nM、15 nM、20 nM和22 nM。 |
||
S7688New |
Ki20227Ki20227 是一种口服活性的 c-Fms tyrosine kinase(CSF1R) 的高选择性抑制剂,对 c-Fms、vascular endothelial growth factor receptor-2 (KDR/VEGFR-2)、stem cell factor receptor (c-Kit) 和 platelet-derived growth factor receptor beta (PDGFRβ) 的IC50值为2 nM、12 nM、451 nM和217 nM。 |
||
S6843New |
X-82 (Vorolanib)X-82 (Vorolanib, CM082)是一种口服的 vascular endothelial growth factor receptor (VEGFR) 和 platelet-derived growth factor receptor (PDGFR) 的多激酶双重抑制剂,并具有抗血管生成和抗肿瘤的活性。 |
||
S0765New |
MAZ51MAZ51 是一种选择性的 vascular endothelial growth factor receptor (VEGFR)-3 (Flt-4) tyrosine kinase 的有效抑制剂。MAZ51 通过 Akt/GSK3β 的磷酸化和 RhoA 的激活来诱导神经胶质瘤细胞的细胞圆缩和G2/M细胞周期停滞。 MAZ51 可抑制多种非VEGFR-3表达肿瘤细胞的增殖并诱导其凋亡。 |
||
S0504New |
SU14813SU14813 (SU 014813)是一种多受体 tyrosine kinase 的抑制剂,对于 VEGFR2、VEGFR1、PDGFRβ 和 Kit (c-Kit) 的IC50值分别为50 nM,2 nM,4 nM和15 nM。SU14813 具有强大的抗血管生成和抗肿瘤活性。 |
||
S0487New |
SulfatinibSulfatinib (HMPL-012, Sufatinib, Surfatinib)是一种有效的、具有高度选择性的 tyrosine kinase 的抑制剂,对于 VEGFR1、VEGFR2、VEGFR3、FGFR1 和 CSF1R 的IC50值分别为2 nM、24 nM、1 nM、15 nM和4 nM。Sulfatinib 在针对晚期NET患者的实验中显示出令人鼓舞的抗肿瘤活性和可控毒性。 |
||
S0377New |
CS-2660 (JNJ-38158471)CS-2660 (JNJ-38158471) 是一种耐受性良好的、口服有效的、高选择性的 VEGFR-2 抑制剂,IC50值为40 nM。CS-2660(JNJ-38158471)还抑制紧密相关的酪氨酸激酶,如 Ret (c-RET) 和 Kit (c-Kit),IC50为180 nM和500 nM,但无明显活性 (>1 microM) 针对VEGFR-1和VEGFR-3。 |
||
S0278New |
SU5614SU5614 (Chloro-SU5416, Chloro-Semaxanib) 是一种小分子 receptor tyrosine kinases (RTK) 的抑制剂,对 VEGFR-2、c-kit 以及野生型和突变型 FLT3 均有抑制作用。SU5614 可减少细胞增殖并诱导凋亡。 |
||
S0290New |
SU5204SU5204 是一种酪氨酸激酶抑制剂,对 FLK-1 (VEGFR-2) 和 HER2 的IC50值分别为4 μM和51.5 μM。 |
||
S6808New |
SU5205SU5205是 VEGF receptor 2 (VEGFR2/FLK-1) 的抑制剂,IC50为9.6 µM。 |
||
S6809New |
SU5214SU5214是 VEGF receptor 2 (VEGFR2/FLK-1) 和 EGFR 的抑制剂,对应的IC50值分别为14.8 µM 和 36.7 µM。 |
||
S6514New |
SU5408SU5408 (VEGFR2 Kinase Inhibitor I)是一种有效、选择性 VEGFR2 Kinase抑制剂,IC50为70 nM。 |
||
S6764New |
TAS-115TAS-115 is a unique VEGFR/Met (c-Met)-targeted inhibitor with IC50 of 30nM and 32nM for rVEGFR2 and rMet (c-Met), respectively. |
||
S2211New |
AG-13958AG-13958 (AG-013958)是VEGFR酪氨酸激酶抑制剂,在临床开发中发现ST给药可治疗与年龄相关性黄斑变性(AMD)的脉络膜新生血管生成。 |
||
S1005 |
AxitinibAxitinib (AG 013736)是一种多靶点抑制剂,作用于 VEGFR1,VEGFR2,VEGFR3,PDGFRβ和c-Kit,在猪主动脉内皮细胞中IC50分别为0.1 nM,0.2 nM,0.1-0.3 nM,1.6 nM和1.7 nM。 |
![]() ![]() Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids. |
|
S1111 |
Foretinib (GSK1363089)Foretinib (GSK1363089, EXEL-2880, XL-880) 是一种ATP竞争性的HGFR和VEGFR抑制剂,对Met (c-Met)和KDR作用最强,在无细胞试验中IC50分别为0.4 nM和0.9 nM。对Ron, Flt-1/3/4, Kit (c-Kit), PDGFRα/β和Tie-2作用效果稍弱,对FGFR1和EGFR几乎没有抑制活性。Phase 2。 |
![]() ![]() c-MET/RON inhibitors restore sensitivity to lapatinib in SK-BR-3-LR cells. Cell growth was determined using the sulforhodamine B assay. The concentration used was 0.1 uM for crizotinib, MGCD-265, XL880, sunitinib, dasatinib, and TAE-684I. The phosphorylation of HER2, AKT and ERK1/2 was determined by Western blotting.
|
|
S1046 |
Vandetanib (ZD6474)Vandetanib (ZD6474) 是一种有效的 VEGFR2 抑制剂,在无细胞试验中IC50为40 nM。同时,也抑制VEGFR3和EGFR,IC50分别为110 nM 和500 nM。对PDGFRβ, Flt-1, Tie-2 和FGFR1作用效果不大,IC50为 1.1-3.6 μM, 对MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt 和 IGF-1R几乎没有作用效果,IC50>10 μM。Vandetanib (ZD6474) 可增加凋亡并通过提高 reactive oxygen species (ROS) 的水平来诱导自噬。 |
![]() ![]() Vandetanib reduced extracellular nitrite levels in endothelial cells. MS1 endothelial cells (ECs) were incubated with 1 mol/L of vandetanib or matched vehicle (dimethyl sulfoxide [DMSO]), 50 ng/mL of vascular endothelial growth factor (VEGF) or matched vehicle (PBS; 0.5 hours), and L-arginine and soluble N-ethylmaleamide sensitive factor attachment protein (SNAP) added (1.5 hours). Vandetanib lowered nitrite levels in MS1 Ecs (*P0.0003). VEGF was used a positive control and increased nitrite levels (**P0.02). These findings indicate that vandetanib lowered endothelial cell NO levels. |
|
S1010 |
Nintedanib (BIBF 1120)Nintedanib (BIBF 1120, Intedanib, Vargatef, Ofev) 尼达尼布是一种有效的三重血管激酶抑制剂,作用于VEGFR1/2/3, FGFR1/2/3和PDGFRα/β,在无细胞试验中IC50分别为34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM和59 nM/65 nM。Phase 3。 |
![]() ![]() Effect of BIBF 1120 on the accumulation of doxorubicin (Dox) and rhodamine 123. The accumulations of doxorubicin a, b and rhodamine 123 c, d were measured by flow cytometric analysis as described in "Materials and Methods". The results are presented as fold change in fluorescence intensity relative to control MDR cells. Columns, means of triplicate determinations; bars, SDs. **P<0.01 versus control group |
|
S1178 |
Regorafenib (BAY 73-4506)Regorafenib (BAY 73-4506, Fluoro-Sorafenib, Resihance, Stivarga) 是一个多靶点抑制剂,作用于VEGFR1,VEGFR2,VEGFR3,PDGFR-β,Kit (c-Kit),RET (c-RET)和Raf-1,在无细胞试验中IC50分别是13 nM,4.2 nM,46 nM,22 nM,7 nM,1.5 nM和2.5 nM。Regorafenib 可诱导自噬。 |
![]() ![]() Hepatoma cells 24 h after plating were treated with vehicle (DMSO), regorafenib (REGO, 0.5 µM), PDE5 inhibitor (sildenafil, 2 µM); or the drugs in combination. 24 hours after treatment cells were isolated and viability determined by trypan blue (n=3, SEM). *P 0.05
|
|
S1035 |
Pazopanib HCl (GW786034 HCl)Pazopanib HCl (GW786034 HCl)是一种新型多靶点抑制剂,作用于VEGFR1,VEGFR2,VEGFR3,PDGFR,FGFR,c-Kit和c-fms,在无细胞试验中IC50分别是10 nM,30 nM,47 nM,84 nM,74 nM,140 nM和146 nM。Pazopanib 可诱导自噬II型细胞死亡。 |
![]() ![]() Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).
|
|
S1017 |
Cediranib (AZD2171)Cediranib (AZD2171, NSC-732208)是一种高效的VEGFR(KDR)抑制剂,IC50为<1 nM,同时也抑制Flt1/4,IC50为5 nM/≤3 nM,此外对c-Kit和PDGFRβ也具有相似的抑制活性,对VEGFR的选择性比PDGFR-α, CSF-1R和Flt3分别高36倍, 110倍 和1000倍以上。Cediranib (AZD2171)可诱导自噬小体累积。Phase 3。 |
![]() ![]() Western blots of EZH2 expression in A549, HCC461, and HCC4006 cells upon treatment with different doses of VEGFR-2-inhibitor AZD2171 (0, 5 and 10 nM). AZD2171 decreased the expression of EZH2 in HCC4006 and HCC461 cells expressing VEGFR-2 in a dose-dependent manner but did not do so in A549 cells lacking expression of VEGFR-2.
|
|
S1264 |
PD173074PD173074 是一种有效的FGFR1抑制剂,在无细胞试验中IC50约为25 nM,也能抑制VEGFR2,IC50为100-200 nM,作用于FGFR1比作用于PDGFR和c-Src选择性高1000倍左右。PD173074 可在胃癌细胞中抑制增殖并促进凋亡。 |
![]() ![]() FGFR inhibitors block signaling in FGFR2-fusion-expressing cells. Activation of FGFR2 and MAPK by FGFR2-AHCYL1 and its suppression by FGFR inhibitors. Lysates from NIH3T3 cells expressing FGFR2-AHCYL1 or EZR-ROS1 (control) treated with vehicle (DMSO), 0.2 and 1 uM BGJ398, and 0.2 and 1 uM PD173074 were immunoblotted with the relevant antibodies. β-Actin was used as a loading control.
|
|
S1018 |
Dovitinib (TKI-258)Dovitinib (TKI-258, CHIR-258)是一种多靶点的RTK抑制剂,在无细胞试验中对III型(FLT3/c-Kit)作用最强,IC50为1 nM/2 nM,同时也作用于IV类(FGFR1/3)和V类(VEGFR1-4) RTKs,IC50为8-13 nM,但对InsR,EGFR,c-Met,EphA2,Tie2,IGF-1R和HER2作用较弱。Phase 4。 |
![]() ![]()
Orthotopic xenografts of HNSCC cell lines (A) SCC-1 and (B) OSC-19 were treated with dovitinib (20 mg/kg/day). In addition, the OSC-19 xenografts were treated with +/ radiation therapy. Marker, mean for triplicate; bars, SE. Statistical significance by unpaired t-test, p < 0.05. |
|
S1003 |
Linifanib (ABT-869)Linifanib (ABT-869, AL39324, RG3635)是一种新型有效的ATP竞争性VEGFR/PDGFR抑制剂,作用于KDR,CSF-1R,Flt-1/3和PDGFRβ,其IC50分别为4 nM,3 nM,3 nM/4 nM和66 nM,对突变激酶依赖性癌细胞(即FLT3)最有效。Linifanib (ABT-869) 可诱导自噬和凋亡。Phase 3。 |
![]() ![]() (B and C) KMCH-1 cells were plated alone (monoculture) or together with PDGF-BB-secreting LX-2 cells (co-culture) in a transwell insert co-culture system (KMCH-1 cells in the bottom wells and LX-2 cells in the inserts; 1:1 ratio) for 2 days. Cells were treated as indicated with vehicle, rhTRAIL (10 ng/ml for 6 h on day 2), rhTRAIL plus imatinib [rhTRAIL:10 ng/ml for 6 h on day 2; Imatinib: 5 μmol/L for 24 h (day2)], or rhTRAIL plus linifanib [rhTRAIL: 10 ng/ml for 6 h on day 2; Linifanib:0.5 μmol/L for 24 h (day2)]. After rhTRAIL treatment for 6 h,KMCH-1 cells were analysed for apoptotic nuclear morphology by DAPI-staining (B) and for DNA fragmentation by transferasemediated dUTP nick end labelling assay (C) with quantification of apoptotic nuclei by fluorescence microscopy. |
|
S1101 |
Vatalanib (PTK787) 2HClVatalanib 2HCl (PTK787, ZK 222584, cpg-79787) 是一种VEGFR2/KDR抑制剂,无细胞试验中IC50为37 nM,对VEGFR1/Flt-1作用稍弱,是VEGFR3/Flt-4抑制作用的18倍。Phase 3。 |
![]() ![]() (Aa-Ja) A single row of BTs on the intact fin and stump after 6-14 dot with PTK787 and 4-12 dot with T. Small BTs appear in the fin regenerate after 8 dot with PTK787 and 6 dot with T (Da,Ea). A small BT cluster appears on the regenerate after 14 dot with PTK787 and 12 dot with T (Ga,Ha). (Ab-Jb) After 4 dot with T, BTs develop on the regenerate, stump and intact fin and continue to grow from 6-12 dot. (Jb) After 12 dot, the blood vessel network of T-treated females is similar to that of males. (Ac-Jc) PTK787-treated females do not possess BTs. (Aa-Ja,Ac-Jc) Neo-angiogenesis and regenerative outgrowth are inhibited in all PTK787-treated females. (Ad-Jd) System water controls regenerate normally and do not grow BTs. B.F., brightfield. Fli, fli1a:EGFP (green). KR21 (red) outlines the BTs. White vertical lines indicate the amputation plane. Scale bar: 100 um.
|
|
S2161 |
RAF265 (CHIR-265)RAF265 (CHIR-265)是一种有效的选择性C-Raf/B-Raf/B-Raf V600E抑制剂,IC50为3-60 nM,对VEGFR2磷酸化表现出有效的抑制作用,无细胞试验中EC50为30 nM。RAF265 (CHIR-265)可诱导细胞周期阻滞和凋亡。Phase 2。 |
![]() ![]() Immunoblots showing levels of phospho-MEK (p-MEK), total MEK (t-MEK), phospho-ERK1/2 (p-ERK1/2) and total ERK1/2 (t-ERK1/2) in A375 cells transduced with a retrovirus expressing BRAFV600E, BRAFV600E/L505H, BRAFV600E/F516G or BRAFV600E/T529N and treated with increasing doses of RAF265. α-tubulin (TUBA) was monitored as a loading control. |
|
S1207 |
Tivozanib (AV-951)Tivozanib (AV-951, KRN-951)是一种有效的,选择性VEGFR抑制剂,作用于VEGFR1/2/3时,IC50分别为0.21 nM/0.16 nM/0.24 nM,也抑制PDGFR和c-Kit,作用于FGFR-1, Flt3, c-Met EGFR和IGF-1R活性较弱。Phase 3。 |
![]() ![]() On-chip angiogenesis assay. Fluorescence imaging of Tg(fli1a:EGFP) embryos at 64 hpf. Transgenic embryos were arrayed and immobilized at 16 hpf and continuously perfused with E3 media containing vehicle control (dimethyl sulfoxide) or selected small-molecule antiangiogenic drugs (Sunitinib and Tivozanib). Right panel: microscopic visualization of patterns of ISV. White arrows: normal ISV growth; blue arrows: partial ISV growth inhibition; and red arrows; complete ISV growth inhibition.
|
|
S1032 |
Motesanib Diphosphate (AMG-706)Motesanib Diphosphate (AMG-706)是一种有效的ATP竞争性的VEGFR1/2/3抑制剂,IC50分别为2 nM/3 nM/6 nM;对Kit (c-Kit)具有相似的抑制活性,对VEGFR选择性比PDGFR和Ret高10倍。Phase 3。 |
![]() ![]() Immunofluorescence staining of choroidal neovascularization (CNV) lesions 14 days after laser photocoagulation. Choroidal flat mounts were fluorescently labeled with F-actin-specific marker phalloidin (green channel), endothelial cell marker CD34 (red channel), and nuclear marker DAPI (blue channel). CNV lesions in topical vehicle-treated eye (A, C, E and G) and topical motesanib-treated eye (B, D, F and H). The scale bar represents 100 um.
|
|
S1164 |
Lenvatinib (E7080)Lenvatinib (E7080)是一种多靶点抑制剂,无细胞试验中,作用于VEGFR2(KDR)/VEGFR3(Flt-4)最有效,IC50为4 nM/5.2 nM,对VEGFR1/Flt-1作用效果稍弱,作用于VEGFR2/3比作用于FGFR1, PDGFRα/β选择性高10倍左右。Lenvatinib (E7080) 也是FGFR1-4、PDGFR、Kit (c-Kit)和RET (c-RET)的抑制剂,并具有强效的抗肿瘤活性。Phase 3。 |
![]() ![]() Dot Plot Distribution of Live, Preapoptotic and Apoptotic Cells after Administration of DuP-697 and E7080 Combination.
|
|
S1084 |
Brivanib (BMS-540215)Brivanib (BMS-540215)是一种ATP竞争性的VEGFR2抑制剂,IC50为25 nM,对VEGFR-1和FGFR-1抑制作用适中,但比作用于PDGFR-β效果强240多倍。Phase 3。 |
![]() ![]() For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Brivanib by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 μM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.
|
|
S1361 |
MGCD-265 analogMGCD-265是一种有效的,多靶点,及ATP竞争性的c-Met和VEGFR1/2/3抑制剂,IC50分别为1 nM, 3 nM/3 nM/4 nM,也抑制Ron和Tie2。Phase 1/2。 |
![]() ![]() c-MET/RON inhibitors restore sensitivity to lapatinib in SK-BR-3-LR cells. The concentration used was 0.1 uM for crizotinib, MGCD-265, XL880, sunitinib, dasatinib, TAE-684, and RON inhibitor I. Columns, means; bars, SEMs (n = 3). The phosphorylation of HER2, AKT and ERK1/2 was determined by Western blotting.
|
|
S1486 |
AEE788 (NVP-AEE788)AEE788 (NVP-AEE788)是一种有效的EGFR和HER2/ErbB2抑制剂,IC50分别为2 nM和6 nM,对VEGFR2/KDR, c-Abl, c-Src,和Flt-1作用效果稍弱,对Ins-R, IGF-1R, PKCα和CDK1没有抑制作用。Phase 1/2。 |
![]() ![]() EGFR-SGLT1 interaction is irresponsive to modulators of EGFR’s tyrosine kinase. A: Immunoprecipitation coupled Western blot analysis ofinteractionsbetween EGFR-HA and SGLT1-FlaginHEK293 cells treatedwith EGF or AEE788. EGFR, total EGFR; pEGFR, phosphorylated EGFR; IP, immunoprecipitation; IB, immunoblot. Input, expression levels of indicated exogenous proteinsin HEK293 whole celllysates used for the IP. |
|
S1181 |
ENMD-2076ENMD-2076 选择性地作用于 Aurora A 和 Flt3,IC50分别为14 nM和1.86 nM,作用于Aurora A比作用于Aurora B选择性高25倍,对RET、SRC、NTRK1/TRKA、CSF1R/FMS、VEGFR2/KDR、FGFR和PDGFRα作用效果稍弱。ENMD-2076 可抑制各种人类实体瘤和造血癌细胞系的生长,其IC50值为0.025至0.7μM,可诱导凋亡和G2/M期停滞。Phase 2。 |
![]() ![]() Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of ENMD-2076.
|
|
S1220 |
OSI-930OSI-930是一种有效的Kit (c-Kit), KDR和CSF-1R抑制剂,IC50分别为80 nM, 9 nM和15 nM,对Flt-1, c-Raf和Lck具有适度的抑制活性,对PDGFRα/β, Flt-3和Abl抑制活性较弱。Phase 1。 |
![]() ![]() RE-luc2P-HEK293 cells were pretreated with 1uM OSI-930 (green), 20uM TBB (blue), 10uM CKI-7 (purple), or 10uM H-89 (orange) for 16 h and infected with Y. enterocolitica WA or Y. pestis Ind195 at MOI 1 and 20, respectively, for 1 h. Following stimulation with 10 ng/ml TNF-α at 5 h post-infection, luciferase activity was measured 24 h post-infection. Results were determined from two independent experiments performed in triplicate. A"*" denotes that the % NF-κβ inhibition using the inhibitors was significantly different (p<0.05) compared to the no drug control (black). The relative NF-κB inhibition by Yersinia infection was determined as a percentage of luciferase activity in bacteria-infected cells relative to luciferase activity in bacteria-free control cells.
|
|
S1171 |
CYC116CYC116是一种有效的Aurora A/B抑制剂,Ki为8.0 nM/9.2 nM,对VEGFR2(Ki为44 nM)作用稍弱,比作用于CDKs效果强50倍,对PKA, Akt/PKB, PKC没有活性,对GSK-3α/β, CK2, Plk1和SAPK2A.没有抑制效果。Phase 1。 |
![]() ![]() Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of CYC116.
|
|
S1363 |
Ki8751Ki8751是一种有效的,选择性的VEGFR2抑制剂,IC50为0.9 nM,作用于VEGFR2比作用于c-Kit, PDGFRα和FGFR-2选择性高40倍以上,对EGFR, HGFR和InsR没有抑制活性。 |
![]() ![]()
Effect of select kinase inhibitors on DF508-CFTR maturation analyzed by immunoblotting. 293MSR-GT cells stably expressing DF508-CFTR were treated with 15 uM kinase inhibitors or 0.3% DMSO (vehicle control), as indicated, grown at 37 °C for 48 h, and the appearance of the mature protein, band C, monitored
by immunoblotting with anti-CFTR antibodies. Band B represents the immature protein. DMSO represents vehicle-alone control, 27 °C represents temperature rescue of F508-CFTR at 27 °C, 37 °C represents untreated DF508-CFTR control, and WT represents WT-CFTR. Top panels depict the anti-CFTR immunoblot and bottom panels depict actin (loading) control. ** represents cellular toxicity.
|
|
S2231 |
TelatinibTelatinib (BAY 57-9352) 是一种有效的VEGFR2/3, c-Kit和PDGFRα抑制剂,IC50分别为6 nM/4 nM, 1 nM和15 nM。Phase 2。 |
![]() ![]() |
|
S2622 |
PP121PP121是一种作用于PDGFR, Hck, mTOR, VEGFR2, Src和Abl的多靶点抑制剂,IC50分别为2 nM, 8 nM, 10 nM, 12 nM, 14 nM和18 nM,也抑制DNA-PK,IC50为60 nM。 |
![]() ![]() PP121 induces apoptosis in ATC cells. CAL62 cells were treated with PP121 at the indicated concentrations for 48 h, followed by PI staining. The nuclei were stained with Hoechst and analyzed using a fluorescent microscope. The representative images are shown.
|
|
S3012 |
PazopanibPazopanib (GW786034) 是一种新型多靶点的VEGFR1,VEGFR2,VEGFR3,PDGFR,FGFR,c-Kit 和 c-Fms/CSF1R抑制剂,无细胞试验中IC50分别为10 nM,30 nM,47 nM,84 nM,74 nM,140 nM 和 146 nM。Pazopanib 可诱导 cathepsin B 的活化和自噬。 |
![]() ![]() Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).
|
|
S1557 |
KRN 633KRN 633是一种ATP竞争性的VEGFR1/2/3抑制剂,IC50为170 nM/160 nM/125 nM,微弱抑制PDGFR-α/β和c-Kit,对细胞中FGFR-1, EGFR和c-Met的磷酸化没有抑制作用。 |
![]() ![]() Inhibited migration of hNSCs toward HeLa cells with the treatment of KRN633, a VEGFR2 inhibitor. The cultured hNSCs were treated with KRN633 for 6 h. After that, the transwell migration assay was performed as described above. The number of migrated cells was counted and the results were presented as means ± SD. Magnification,× 200. *P < 0.05 vs. KRN633 non-treated
GESTECs. (A) Migrated HB1.F3.CD cells. (B) Migrated HB1.F3.CD.IFN-β cells.
|
|
S2842 |
SAR131675SAR131675是一种VEGFR3抑制剂,无细胞试验中IC50/Ki为23 nM/12 nM,作用于VEGFR3比作用于VEGFR1/2选择性高50和10倍,对Akt1, CDKs, PLK1, EGFR, IGF-1R, c-Met, Flt2等几乎没有作用活性。 |
![]() ![]() Blockade of IPC-induced ischemic tolerance by the VEGFR-3 inhibitor SAR131675. (A) Representative images of FJ-stained brain sections from sham + SARH (i), sham-IPC + SI + Veh (ii), IPC + SI + Veh (iii) and IPC + SI + SARH (iv) groups. Note that there were more degenerated neurons in the IPC + SI + SARH group receiving SAR131675 of 50 mg/kg as an initial dose than in the IPC + SI + Veh group. Scale bar = 50 μm. (B) The quantitative analysis shows the number of FJ-positive degenerated neurons in the CA1 subregion of the different treatment groups including the IPC + SI + SARL group receiving SAR131675 of 25 mg/kg as an initial dose. Data are presented as the mean ± SEM; # p < 0.05 compared with the sham-IPC + SI + Veh group; *p < 0.05 compared with the IPC + SI + Veh group. (C) Representative images of NeuN immunofluorescence in the sham + SARH (i), sham-IPC + SI + Veh (ii), IPC + SI + Veh (iii) and IPC + SI + SARH (iv) groups. Note that NeuN-immunofluorescence in the IPC + SI + SARH group was reduced compared with the IPC + SI + Veh group. Scale bar = 50 μm. (D) The quantitative analysis shows the number of NeuN-positive intact pyramidal neurons in the CA1 subregion for the different treatment groups. Data are presented as the mean ± SEM; #p < 0.05 compared with the sham-IPC + SI + Veh group; *p < 0.05 compared with the IPC + SI + Veh group. |
|
S2201 |
BMS-794833BMS-794833是一种有效的,ATP竞争性Met (c-Met)/VEGFR2抑制剂,IC50为1.7 nM/15 nM,也抑制Ron, Axl和Flt3,IC50低于3 nM;是BMS-817378的前体药物。 Phase 1。 |
||
S7397 |
SorafenibSorafenib (BAY 43-9006) 是Raf-1和B-Raf的多重激酶抑制剂,无细胞试验中IC50分别为6 nM和22 nM。Sorafenib 还可抑制VEGFR-2、VEGFR-3、PDGFR-β、Flt-3和c-KIT,对应的IC50值分别为90 nM、20 nM、57 nM、59 nM和68 nM。Sorafenib 可诱导autophagy、apoptosis并激活ferroptosis,Sorafenib 具有抗肿瘤活性。 |
![]() ![]() Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.
|
|
S4001 |
Cabozantinib malate (XL184)Cabozantinib malate (XL184)是Cabozantinib的苹果酸盐,是有效的VEGFR2抑制剂,IC50为0.035 nM,也抑制c-Met, RET (c-RET), Kit (c-Kit), Flt-1/3/4, Tie2和AXL,无细胞试验中IC50分别为1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM和7 nM。Cabozantinib malate (XL184)可诱导细胞凋亡。 |
![]() ![]() Effects of AXL inhibitors on induction of pAKT and rescue of pERK following AXL overexpression. R428, 500 nmol/L; XL184, 3 umol/L; XL880, 100 nmol/L; in the presence or absence of 2 umol/L PLX4720. shAXL is a positive control.
|
|
S1138 |
Brivanib Alaninate (BMS-582664)Brivanib Alaninate (BMS-582664)是BMS-540215的前体药物,是一种ATP竞争性的VEGFR2抑制剂,IC50为25 nM。 |
![]() ![]() |
|
S2859 |
Golvatinib (E7050)Golvatinib (E7050)是c-Met和VEGFR-2双重抑制剂,IC50分别为14 nM和16 nM,不抑制bFGF刺激的HUVEC生长(浓度高达1000 nM)。Phase 1/2。 |
![]() ![]() PC-9/LMC-GR cells (2 × 105 cells/well) were incubated in 6-well plates with various concentrations of gefitinib with or without crizotinib (1 μmol/L) or golvatinib (1 μmol/L) for 1 hour. Cell lysate were obtained and subjected to immunoblotting with antibodies toward the indicated molecules.
|
|
S2845 |
Semaxanib (SU5416)Semaxanib (SU5416)是一种有效的,选择性的VEGFR(Flk-1/KDR)抑制剂,IC50为1.23 μM,作用于VEGFR比作用于PDGFRβ选择性高20倍,对EGFR, InsR和FGFR没有作用活性。Phase 3。 |
![]() ![]() Injected tumor cells move to the tail via blood vessels. Tg (flil1:egfp) embryos at 20 hpf were treated with 2 μM SU5416 for 1 hr (+SU5416) to inhibit vasculogenesis24; the control fish were treated with 0.02% DMSO for 1 hr (-SU5416). After 1 hr, SU5416 or DMSO was washed out by changing fish media. At 48 hpf, tfRFP-B16 cells were injected into the pericardium cavity of fish. Representative images show that tumor cells moved to the tail in a drug-free larva, while no tumor cells moved to the tail in a drug-treated larva after new vessels were inhibited by SU5416. Insets are enlarged images from each corresponding tip of the tail indicated by white arrows. Dashed white lines mark extravasated tumor cells at 12 hpi. Vessels are green and tumor cells are red. –SU5416, 6 other larvae exhibit similar behaviors; +SU5416, 3 other larvae exhibit similar behaviors. Scale bars, 500 μm. Insets, 100 μm.
|
|
S2897 |
ZM 306416ZM 306416 (CB 676475) 是一种VEGFR(Flt和KDR)抑制剂,作用于VEGFR1,IC50为0.33 μM,也抑制EGFR,IC50为<10 nM。 |
![]() ![]() Panels D-F show morphological changes of RBEC cells due to Sema3A treatment. RBECs were fixed after the indicated treatment and stained with phalloidin conjugated with rhodamine (red color) and counter stained with DAPI (blue color). F-actin stress fibres are very clear in untreated cells (D). Sema3A treatment caused disruption of F-actin inside the cells. Densely packed bundles of cortical actin filaments started to appear along cell membranes (arrows) over the course of treatment with Sema3A. Antibodies and inhibitors against receptors of Sema3A were pre-incubated with the cells for 15 min before the addition of Sema3A. Antibodies to VEGFR1 and NRP2 (panel E) and the inhibitor Zm 306416 (selective to VEGFR1, panel F) were effective in ameliorating the effect of Sema3A. Scale bar=20 μm. |
|
S2896 |
ZM 323881 HClZM 323881 HCl是一种有效的,选择性的VEGFR2抑制剂,IC50为<2 nM,对VEGFR1, PDGFRβ, FGFR1, EGFR和ErbB2几乎没有活性。 |
![]() ![]() (A) Fluorescence microscopic analysis of Hoechst 33342 staining of NCIH460 and NCI-H460/MX20 cells. Cells were treated as described in ‘2. Materials and Methods’. Scale bar, 10 μm. (B) Effects of ZM323881 on intracellular accumulation of [3H]-mitoxantrone in NCI-H460 and NCI-H460/MX20 cells. (C) Efflux of [3H]-mitoxantrone in the absence and presence of inhibitors in NCI-H460 cells. (D) Efflux of [3H]-mitoxantrone in the absence and presence of inhibitors in NCI-H460/MX20 cells.
|
|
S2018 |
ENMD-2076 L-(+)-Tartaric acidENMD-2076 L-(+)-Tartaric acid 是ENMD-2076的酒石酸,选择性作用于Aurora A和VEGFR(Flt3),IC50分别为14 nM和1.86 nM,作用于Aurora A比作用于Aurora B选择性高25倍,对VEGFR2/KDR和VEGFR3, FGFR1和FGFR2和PDGFRα作用效果稍弱。Phase 2。 |
![]() ![]() Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of ENMD-2076.
|
|
S7057 |
LY2874455LY2874455是一个泛FGFR的抑制剂,对FGFR1,FGFR2, FGFR3, 和FGFR4的IC50值分别为2.8 nM, 2.6 nM, 6.4 nM,以及6 nM。并且也能抑制VEGFR2的活性,IC50为7 nM。Phase 1。 |
![]() ![]() A: Overall structure of LY2874455/FGFR4 complex. B: The diagram of LY2874455. C: Fo-Fc omit map of LY2874455 in the FGFR4/LY2874455 complex. The electron density is superimposed with the final model. D: The DFG motif conformation of FGFR4. Active ApoFGFR4 DFG-in conformation is shown in blue (PDB: 4QQT); FGFR4/Ponatinib DFG-out conformation is shown in yellow (PDB: 4UXQ); FGFR4/BLU9931 DFG-in conformation is shown in pink (PDB: 4XCU); FGFR4/LY2874455 DFG-in conformation is shown in grey (this work). LY2874455 is highlighted in brown.
|
|
S8189 |
BAW2881 (NVP-BAW2881)BAW2881 (NVP-BAW2881)是一种新型的VEGFR酪氨酸激酶抑制剂。在1.0-4.3 nM浓度下能有效地抑制VEGFR1-3;在45-72 nM的浓度下,抑制PDGFRβ, c-Kit和RET (c-RET)。 |
||
S6520 |
WHI-P180WHI-P180是多种激酶的抑制剂,对RET (c-RET)和KDR的IC50值分别为4.5 nM和66 nM。 |
||
S6543 |
ZD-4190ZD-4190是VEGF RTK抑制剂,对KDR和Flt-1的IC50值分别为29 ± 4 nM和708 ± 63 nM。 |
||
S6535 |
SU1498SU1498是KDR抑制剂,IC50为0.7 μM,可在内皮细胞中刺激磷酸化ERK1/2的累积。 |
||
S7667 |
SU5402SU5402是一种有效的多靶点受体激酶抑制剂,对VEGFR2,FGFR1,和PDGF-Rβ的IC50分别为20 nM,30 nM,和510 nM。 |
![]() ![]() Four FGFR inhibitors, namely PD-173074 (PD-74), PD-166866 (PD-66), SU5402 (SU54) and NVP-BGJ398 (BG-98), inhibit A673, SKNMC, POE, RDES and SKES Ewing cell growth in vitro in a dose-dependent manner, whereas normal cells (IMR90 fibroblasts) remained unaffected. PD-74 proved to be most effective in four out of five Ewing sarcoma cell lines tested. Cells were grown in 10% FBS conditions and cell proliferation was measured after 72 h using a Resazurin assay.
|
|
S8721 |
PDGFR inhibitor 1PDGFR inhibitor 1是一种具有口服活性的Kit (c-Kit)和PDGFR抑制剂,具有潜在的抗肿瘤活性。它还能抑制好几种其他激酶,包括VEGFR2、TIE2、PDGFR-beta和CSF1R,因此进而抑制肿瘤细胞的生长。 |
||
S7765 |
Dovitinib (TKI258) LactateDovitinib (TKI258, CHIR258) Lactate是Dovitinib的乳酸盐,Dovitinib是一种多靶点的PTK抑制剂,主要对第III类(FLT3/c-Kit)发挥作用,IC50为1 nM/2 nM,对第IV 类(FGFR1/3)和第V 类(VEGFR1-4) RTKs也有效,IC50为8-13 nM,对InsR,EGFR,c-Met,EphA2,Tie2,IGFR1 和HER2作用较差。Phase 4。 |
![]() ![]() (c) Percent survival for the AGS cancer cell line is shown with FGFR2 inhibitors of varying specificity. (d) The KatoIII diffuse gastric cancer cell line was treated with FGFR2 inhibitors of varying specificity. The Y-axis depicts percent survival versus the X-axis with log concentrations. In all panels, error bars represent standard error of the mean. The difference in percent cell survival between KatoIII and AGS cells was statistically significant (P <0.05) at the three highest concentrations of all drugs, except Brivanib which was only significant at the highest concentration. |
|
S5272 |
Toceranib phosphateToceranib phosphate (Palladia, SU11654), the phosphate salt of toceranib, is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family, including Flk-1/KDR, PDGFR, and Kit with Ki values of 6 nM and 5 nM for Flk-1/KDR and PDGFRβ, respectively. |
||
S5242 |
Cediranib MaleateCediranib Maleate (AZD-2171) is the maleate salt of Cediranib, which is a potent inhibitor of VEGFR with IC50 of <1 nM and also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM. |
||
S8188 |
BFH772BFH772是一种新型的、有效的、可口服的VEGFR2抑制剂,IC50为3 nM。 |
||
S5240 |
lenvatinib MesylateLenvatinib Mesylate 是一种合成、具有口服活性的 tyrosine kinase 的抑制剂,可抑制血管内皮生长因子受体(VEGFR1-3),成纤维细胞生长因子受体(FGFR1-4),血小板衍生生长因子受体(PDGFRα),干细胞因子受体(Kit (c-Kit)),并在转染过程中重新排列(RET (c-RET))。甲磺酸来伐替尼具有潜在的抗肿瘤活性。 |
||
S5667 |
Fruquintinib (HMPL-013)Fruquintinib (HMPL-013) is a small molecule inhibitor with strong potency and high selectivity against VEGFR family. It inhibits VEGFR 1, 2, 3, with IC50 values of 33 nM, 35 nM and 0.5 nM, respectively and shows only weak inhibition of RET, FGFR-1 and c-kit kinases. |
||
S8882 |
ODM-203ODM-203是FGFR 和 VEGFR的双重抑制剂,对重组FGFR1,FGFR2,FGFR3,FGFR4,VEGFR1,VEGFR2和VEGFR3的ic50分别为11 nM,16 nM,6 nM,35 nM,26 nM,9 nM,5 nM。 |
||
S8401 |
Erdafitinib (JNJ-42756493)Erdafitinib (JNJ-42756493)是有效的、具有选择性和口服生物活性的泛成纤维细胞生长因子受体FGFR抑制剂,具有潜在的抗肿瘤活性。Erdafitinib 也能结合RET (c-RET)、CSF-1R、PDGFR-α/PDGFR-β、FLT4、Kit (c-Kit)和VEGFR-2并可诱导细胞凋亡。 |
![]() ![]() E, Continuous ERK phosphorylation in FGFR inhibitor resistant cells under 24-hour treatment with 1 μmol/L BGJ398 assessed by immunoblotting. FGFR inhibitors: AZD4547, BGJ398, and JNJ-42756493 |
|
S6526 |
SKLB 610SKLB-610是一种多靶点的酪氨酸激酶 (tyrosine kinases)抑制剂。它对VEGFR2的抑制作用最为有效,是FGFR2和PDGFR的弱抑制剂。 |
||
S7781 |
SunitinibSunitinib (SU11248) 是一种多靶点 RTK 抑制剂,以VEGFR2(Flk-1)和PDGFRβ为靶点,IC50为80 nM 和 2 nM,对c-Kit也有抑制作用。Sunitinib 还是 IRE1α 的自磷酸化活性的剂量依赖性抑制剂。 舒尼替尼可诱导自噬和细胞凋亡。 |
![]() ![]() Sunitinib decreases FLT-3 and RET phosphor ylation but increases ERK phosphorylation in a time-dependent manner. H295R and SW13 cells were treated with sunitinib (10 nM) for various time points as indi-cated. Cell lysates were prepared and phospho-FLT-3, RET, and ERK levels were monitored by Western Blot-ting. Re-probing against FLT-3, RET, and ERK was done to ensure equal protein loading. |
|
S8573 |
Sitravatinib (MGCD516)Sitravatinib (MGCD516, MG-516)是一种新型的、靶向多种参与调节S180肉瘤细胞生长的RTKs的小分子抑制剂,包括c-Kit, PDGFRβ, PDGFRα, c-Met和Axl。 |
||
S7258 |
SKLB1002SKLB1002 是一种与ATP竞争的强效VEGFR2抑制剂,其IC50为32 nM. |
![]() ![]() Protein expressions of VEGFR2, p-VEGFR2, FAK, p-FAK, ERK, p-ERK and VE-cadherin in HCT116 cells with or without SKLB1002 treatment were determined by western blotting analysis. Representative data of three experiments are shown
|
|
S5793 |
Motesanib (AMG-706)Motesanib (AMG-706)是一种具有口服生物活性的受体酪氨酸激酶 (receptor tyrosine kinase)抑制剂,对VEGFR1, VEGFR2, VEGFR3, Kit, PDGFR和Ret的IC50值分别为2、3、6、8、84和59 nM。 |
||
S8696 |
2-D082-D08 (2',3',4'-trihydroxy flavone) 是一种具有细胞透性的蛋白类泛素化(protein sumoylation)抑制剂。它还能抑制Axl, IRAK4, ROS1, MLK4, GSK3β, RET (c-RET), KDR和PI3Kα,IC50分别为0.49, 3.9, 5.3, 9.8, 11, 11, 17和35 nM。 |
||
S6412 |
AltiratinibAltiratinib (DCC-2701) 是有效的TRK, Met (c-Met), TIE2和VEGFR2激酶抑制剂,对TRKA, B和C的IC50分别为0.9 nM, 4.6 nM和0.8 nM。它抑制Met (c-Met)和Met (c-Met)突变体的IC50范围为0.3-6 nM。 |
||
S4686 |
Vitamin EVitamin E (D-alpha-Tocopherol) 是一种脂溶性的维生素,具有有效的抗氧化特性。它是有效的过氧化氢自由基清除剂并在很多组织中,非竞争性地抑制环氧酶活性。同时通过抑制VEGF基因转录,抑制血管生成和肿瘤休眠。 |
||
S7003 |
AZD2932AZD2932 是一种有效的多靶点蛋白酪氨酸激酶抑制剂,对VEGFR-2,PDGFRβ,Flt-3,和 c-Kit 的 IC50 分别为 8 nM,4 nM,7 nM,和 9 nM。 |
||
S8726 |
Anlotinib (AL3818) dihydrochlorideAnlotinib (AL3818) 是一种高度有效的VEGFR2选择性抑制剂,IC50小于1 nM。它在临床试验中具有广谱性抗肿瘤潜力。稀释请用生理盐水,请勿用PBS稀释,可能产生沉淀。 |
||
S5234 |
Nintedanib Ethanesulfonate SaltNintedanib (Intedanib, BIBF 1120) is a small molecule tyrosine-kinase inhibitor with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β, respectively. |
||
S5077 |
Regorafenib MonohydrateRegorafenib (BAY-734506, Fluoro-sorafenib, Resihance, Stivarga) Monohydrate 是一种新型口服的多重激酶抑制剂,对VEGFR1、小鼠VEGFR2、小鼠VEGFR3、PDGFR-β、Kit (c-Kit)、RET (c-RET)、RAF-1、B-RAF和B-RAF(V600E)的IC50分别为13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM。 |
||
S2366 |
Taxifolin (Dihydroquercetin)Taxifolin(Dihydroquercetin)是一种二氢黄酮醇类,是一种黄酮类化合物。是I型VEGFR2 kinase的抑制剂。 |
目录号 | 产品描述 | 文献引用 | 实验数据 |
---|---|---|---|
A2003New |
Ramucirumab (anti-VEGFR2)Ramucirumab (anti-VEGFR2) 是IgG1类的单克隆抗体,可与 VEGF-R2 结合并阻止其激活,其阻断KDR与VEGF结合的 IC50 值为0.8 nM;MW: 143.6 KD。 |
||
A2006 |
Bevacizumab (anti-VEGF)Bevacizumab (anti-VEGF, Avastin) 是一种人源化的anti-VEGF单克隆抗体,是VEGF的抑制剂。可与所有人源VEGF-A亚型(和具有生物活性的蛋白水解片段)结合、中和。MW:149 KD。 |
![]() ![]() VEGFA expression in the indicated cells treated with or without bevacizumab or transfected with VEGFA or shVEGFA.
|